Design, Synthesis, and Biological Evaluation of PKD Inhibitors. George, K. M., Frantz, M., Bravo-Altamirano, K., LaValle, C. R., Tandon, M., Leimgruber, S., Sharlow, E. R., Lazo, J. S., Wang, Q. J., & Wipf, P. Pharmaceutics, 3(2):186–228, April, 2011. ![Design, Synthesis, and Biological Evaluation of PKD Inhibitors [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Protein kinase D (PKD) belongs to a family of serine/threonine kinases that play an important role in basic cellular processes and are implicated in the pathogenesis of several diseases. Progress in our understanding of the biological functions of PKD has been limited due to the lack of a PKD-specific inhibitor. The benzoxoloazepinolone CID755673 was recently reported as the first potent and kinase-selective inhibitor for this enzyme. For structure-activity analysis purposes, a series of analogs was prepared and their in vitro inhibitory potency evaluated.
@article{george_design_2011,
title = {Design, {Synthesis}, and {Biological} {Evaluation} of {PKD} {Inhibitors}},
volume = {3},
copyright = {https://creativecommons.org/licenses/by/3.0/},
issn = {1999-4923},
url = {https://www.mdpi.com/1999-4923/3/2/186},
doi = {10.3390/pharmaceutics3020186},
abstract = {Protein kinase D (PKD) belongs to a family of serine/threonine kinases that play an important role in basic cellular processes and are implicated in the pathogenesis of several diseases. Progress in our understanding of the biological functions of PKD has been limited due to the lack of a PKD-specific inhibitor. The benzoxoloazepinolone CID755673 was recently reported as the first potent and kinase-selective inhibitor for this enzyme. For structure-activity analysis purposes, a series of analogs was prepared and their in vitro inhibitory potency evaluated.},
language = {en},
number = {2},
urldate = {2024-07-17},
journal = {Pharmaceutics},
author = {George, Kara M. and Frantz, Marie-Céline and Bravo-Altamirano, Karla and LaValle, Courtney R. and Tandon, Manuj and Leimgruber, Stephanie and Sharlow, Elizabeth R. and Lazo, John S. and Wang, Q. Jane and Wipf, Peter},
month = apr,
year = {2011},
pages = {186--228},
}
Downloads: 0
{"_id":"pMmmbezpXRByTbPbP","bibbaseid":"george-frantz-bravoaltamirano-lavalle-tandon-leimgruber-sharlow-lazo-etal-designsynthesisandbiologicalevaluationofpkdinhibitors-2011","author_short":["George, K. M.","Frantz, M.","Bravo-Altamirano, K.","LaValle, C. R.","Tandon, M.","Leimgruber, S.","Sharlow, E. R.","Lazo, J. S.","Wang, Q. J.","Wipf, P."],"bibdata":{"bibtype":"article","type":"article","title":"Design, Synthesis, and Biological Evaluation of PKD Inhibitors","volume":"3","copyright":"https://creativecommons.org/licenses/by/3.0/","issn":"1999-4923","url":"https://www.mdpi.com/1999-4923/3/2/186","doi":"10.3390/pharmaceutics3020186","abstract":"Protein kinase D (PKD) belongs to a family of serine/threonine kinases that play an important role in basic cellular processes and are implicated in the pathogenesis of several diseases. Progress in our understanding of the biological functions of PKD has been limited due to the lack of a PKD-specific inhibitor. The benzoxoloazepinolone CID755673 was recently reported as the first potent and kinase-selective inhibitor for this enzyme. For structure-activity analysis purposes, a series of analogs was prepared and their in vitro inhibitory potency evaluated.","language":"en","number":"2","urldate":"2024-07-17","journal":"Pharmaceutics","author":[{"propositions":[],"lastnames":["George"],"firstnames":["Kara","M."],"suffixes":[]},{"propositions":[],"lastnames":["Frantz"],"firstnames":["Marie-Céline"],"suffixes":[]},{"propositions":[],"lastnames":["Bravo-Altamirano"],"firstnames":["Karla"],"suffixes":[]},{"propositions":[],"lastnames":["LaValle"],"firstnames":["Courtney","R."],"suffixes":[]},{"propositions":[],"lastnames":["Tandon"],"firstnames":["Manuj"],"suffixes":[]},{"propositions":[],"lastnames":["Leimgruber"],"firstnames":["Stephanie"],"suffixes":[]},{"propositions":[],"lastnames":["Sharlow"],"firstnames":["Elizabeth","R."],"suffixes":[]},{"propositions":[],"lastnames":["Lazo"],"firstnames":["John","S."],"suffixes":[]},{"propositions":[],"lastnames":["Wang"],"firstnames":["Q.","Jane"],"suffixes":[]},{"propositions":[],"lastnames":["Wipf"],"firstnames":["Peter"],"suffixes":[]}],"month":"April","year":"2011","pages":"186–228","bibtex":"@article{george_design_2011,\n\ttitle = {Design, {Synthesis}, and {Biological} {Evaluation} of {PKD} {Inhibitors}},\n\tvolume = {3},\n\tcopyright = {https://creativecommons.org/licenses/by/3.0/},\n\tissn = {1999-4923},\n\turl = {https://www.mdpi.com/1999-4923/3/2/186},\n\tdoi = {10.3390/pharmaceutics3020186},\n\tabstract = {Protein kinase D (PKD) belongs to a family of serine/threonine kinases that play an important role in basic cellular processes and are implicated in the pathogenesis of several diseases. Progress in our understanding of the biological functions of PKD has been limited due to the lack of a PKD-specific inhibitor. The benzoxoloazepinolone CID755673 was recently reported as the first potent and kinase-selective inhibitor for this enzyme. For structure-activity analysis purposes, a series of analogs was prepared and their in vitro inhibitory potency evaluated.},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2024-07-17},\n\tjournal = {Pharmaceutics},\n\tauthor = {George, Kara M. and Frantz, Marie-Céline and Bravo-Altamirano, Karla and LaValle, Courtney R. and Tandon, Manuj and Leimgruber, Stephanie and Sharlow, Elizabeth R. and Lazo, John S. and Wang, Q. Jane and Wipf, Peter},\n\tmonth = apr,\n\tyear = {2011},\n\tpages = {186--228},\n}\n\n\n\n\n\n\n\n","author_short":["George, K. M.","Frantz, M.","Bravo-Altamirano, K.","LaValle, C. R.","Tandon, M.","Leimgruber, S.","Sharlow, E. R.","Lazo, J. S.","Wang, Q. J.","Wipf, P."],"key":"george_design_2011","id":"george_design_2011","bibbaseid":"george-frantz-bravoaltamirano-lavalle-tandon-leimgruber-sharlow-lazo-etal-designsynthesisandbiologicalevaluationofpkdinhibitors-2011","role":"author","urls":{"Paper":"https://www.mdpi.com/1999-4923/3/2/186"},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/MicaelCunha","dataSources":["c5omsHuXiMyvDCiav"],"keywords":[],"search_terms":["design","synthesis","biological","evaluation","pkd","inhibitors","george","frantz","bravo-altamirano","lavalle","tandon","leimgruber","sharlow","lazo","wang","wipf"],"title":"Design, Synthesis, and Biological Evaluation of PKD Inhibitors","year":2011}